

Studies on respiratory affections in calves due To *Mycoplasma* in Dakahlia and Sharkia Governorates.

*Abd El-Aziz, E. E ; *Dardeer, M.A; **Taha, M.F; *Hassan, A.M and *Mona, M. Shaker

*Animal Health Research Institute-Mycoplasma Department-Dokki-Giza-Egypt

**Animal Health Research Institute-Zagazig branch

Abstract

This study was carried on calves suffering from respiratory signs, fever, sometimes anorexia with age ranged from 2 month to 2 years. Eighty one samples were collected at the time of initial treatment (69 nasopharyngeal swabs and 12 lung tissues) from two main Governorates Dakahlia and Sharkia. The incidence of *Mycoplasma* isolation was 16.7% from DaKahlia and 26.7% from Sharkia. Six isolates were identified as *Mycoplasma bovirhinis*, five isolates were *Mycoplasma arginini* and seven isolates were *Mycoplasma bovis* from two big farms in Sharkia Governorate. PCR test was used to confirm the isolation by using the common gene 16SrRNA for ruminant *Mycoplasmas* which gave characteristic band at 1000bp. *M. bovirhinis* was confirmed using 16SrRNA which gave specific fragment at 316bp, while *Mycoplasma bovis* was confirmed using VsPA gene which gave specific fragment ranged between 342-500 bp. depending on the locality of isolation. Sensitivity test for some *Mycoplasma* isolates using MIC method revealed that Draxxin (Tulathromycin) has the lowest MIC for both *Mycoplasma bovirhinis* and *Mycoplasma arginini* with range (0.0048-0.007), while Enrofloxacin has the lowest MIC against *Mycoplasma bovis* (0.014).

Key words: *Mycoplasma bovis*, *Mycoplasma bovirhinis*, *Mycoplasma arginini*, Tulathromycin.

Introduction

Bovine respiratory disease (BRD) complex is a major disease of calves (Virtala *et al.*, 1996 and Duchemin, 2004). Clinical symptoms typically appear after a stressful event such as transportation and grouping. BRD is a multifactorial disease. The role of class mollicutes specially *Mycoplasma bovis* is an active agent in cases of bovine respiratory disease (BRD) is poorly defined. *Mycoplasma bovis* is the predominant pathogen isolated from the middle ear of calves suffering from otitis media (Haines *et al.*, 2001 and Sharter *et al.*, 2002). Multiple *mycoplasma* species as *Mycoplasma bovirhinis*, *Mycoplasma dispar*, *Ureaplasma diversum* and even *Mycoplasma canis* have been isolated from respiratory healthy calves, (Virtala *et al.*, 1996 and Duchemin, 2004). *Mycoplasma bovirhinis* is a troublesome agent as a secondary invader in respiratory disease, because it is the most commonly isolated from the nasal cavity of cattle with respiratory dis-

ease, (Gourlay and Howard, 1979). The role of these organisms as primary or secondary pathogen unclear, the economic impact of mycoplasmosis whoever has been estimated to be significant in the beef industry due to weight loss and health consequences (Lamm *et al.*, 2004).

Franco *et al.* (2004), recorded that bacteria from class mollicutes specifically *Mycoplasma bovis* has been associated with pneumonia in cattle, and these organisms are frequently identified from chronic respiratory disease cases, (Thomas and Ball, 2002, Wiggins *et al.*, 2007). In Europe, it is responsible for at least a quarter to a third of all calf pneumonia, (Lamm *et al.*, 2004). Pneumonia is a major cause of economic losses because of decreased production, high levels of mortality and morbidity and increased veterinary and labor costs, (Ganaba *et al.*, 1995). Moreover calves experienced pneumonia at early age might have severe depression in the production capabilities

in the future, (Sayed and Zaitoun, 2009). Previous research documents that these organisms may be found in the nasal discharge from healthy and chronically ill animals (Nicholas and Ayling, 2003).

So the purpose of this study was to study the role of mycoplasmosis as a cause of respiratory infection in calves by using culture procedures and polymerase chain reaction (PCR) to determine its prevalence in field cases with BRD at the time of initial treatment.

Material and Methods

Samples:

A total of 81 samples were collected from calves, 69 deep nasal swabs and 12 lung tissues, (36 from Dakahlia Governorate and 45 from Sharkia Governorate) with age ranged from 2 months to 2 years, these animals suffering from respiratory signs as cough, dyspnea and nasal discharge, some times fever with different degrees of anorexia.

Culture procedures (Sabry and Ahmed, 1975):

The collected samples were transported to PPLO broth and incubated at 37°C for 24 hours; the incubated broth samples were plated on PPLO agar plates under reduced oxygen tension in humidified candle jar and examined for mycoplasma colonies after 48 hours then daily up to 7-10 days for fried egg colonies.

Biochemical identification:

1-Digitonin test (Frundt *et al.*, 1973).

This test was made to differentiate between genus mycoplasma and genus acholeplasma depending on sterol requirement for growth, the cultivated plates were incubated in suitable condition and examined for inhibition zone, mycoplasmas are digitonin positive showing marked inhibition zone, while acholeplasma are digitonin negative.

2-Glucose fermentation test (Erno and Stipkovits, 1973).

The suspected cultures were inoculated into glucose medium with control and incubated at 37 °C, if the color changed from red to yellow or orange is considered positive.

3-Arginine deamination test (Erno and Stipkovits, 1973).

The purified culture was examined to its ability to hydrolyze arginine, if the color changed from red to pink is considered positive.

4-Identification by PCR:

The biochemically characterized mycoplasma isolates were investigated by PCR test for identification.

DNA extraction:

1-Extraction of chromosomal DNA (Fan *et al.*, 1995):

Five ml quantity of overnight incubated culture from each Mycoplasma isolate was centrifuged in a micro-centrifuge at 13000 rpm for 3 minutes. The cell pellets were washed twice in 100 µl of 150 mM phosphate buffered saline (PBS, pH 7.2) and suspended in 25 µl PBS. The cell suspension was heated directly at 100 °C for 10 minutes in a heat block and then put on ice for 10 minutes. Finally, the cell suspension was centrifuged for 3 minutes, and chromosomal DNA was collected and stored at 4°C.

Oligonucleotide primers encoding 16S common gene for ruminant Mycoplasma and VspA specific gene for *Mycoplasma bovis* (Alberto *et al.*, 2006), while *Mycoplasma bovirhinis* was 16SrRNA specific gene as described by (Kobayashi *et al.*, 1998).

Primer of 16SrRNA common gene.

16Smuniv F: 5'-AGA CTC CTA CGG GAG GCA GCA-3'.

16Smuniv R: 5'-ACT AGC GAT TCC GAC TTC ATG-3'.

Primer of 16SrRNA gene of *Mycoplasma bovirhinis*

Mbr F: 5'-GCT GAT AGA GAG GTC TAT CG-3'

Mbr R: 5'-ATT ACT CGG GCA GTC TCC-3'

Primer of Vsp A specific gene of *Mycoplasma bovis*

MYB F: 5'-CTT GGA TCA GTG GCT TCA TTA GC-3'.

MYB R: 5'-GTC ATC ATG CGG AAT TCT TGG GT-3

The sequence of 16SrRNA gene was amplified a product at 1000 base pair (bp) while a specific gene of *Mycoplasma bovis* (VspA) was amplified a product at 420 bp. Primers were pre-

pared by Sigma Company.

PCR procedures (Alberto *et al.*, 2006):

The PCR reaction mixture (total volume 50µl.PCR was performed on a progene programmable thermal controller (UK).

2- Cycling procedures:

The amplification was performed by heating the sample for 9 minutes at 94 °C then 35 cycles of denaturation for 45 sec. at 94 °C, annealing for 1 minute at 60 °C, and extenuation

step for 1.5 min. at 72 °C, a final extenuation step at 72°C held for 5 min. The analysis of PCR products was performed by using 10µl of amplified PCR product, mixed with 2µl loading buffer and electrophoresed through 1.5% agarose gel and DNA was visualized by UV fluorescence after ethidium bromide staining and then photographed.

3- Antimicrobials: The antimicrobials used and the form of which they are available and

Table (1). Antimicrobial drugs used for MIC determination.

Drug	Group	Form used	Source
Draxxin	Macrolide	25% Solution	Pfizer USA
Enrofloxacin	Quinolones	10% Solution	Alex.Vet.Egypt
Noflor	Florofenicol	10% Solution	Schering plough
Pan terramycin	Tetracycline	3% Solution	Pfizer Egypt
Tylocin 200	Macrolide	20% Solution	Avico Jordan

Sterile stock solution:

Sterile stock solutions containing 160µg/ml were prepared from each drug in distilled water and stored at 4°C or used freshly.

Titration of Mycoplasmas:

For each Mycoplasma isolate, the number of color changing units (ccu) was determined by the method described by **Tylor- Robinson (1983)**. A titer of 10^3 - 10^4 cfu/ 0.2ml was required for test proper (**Senterfit, 1983**).

Determination of minimal inhibitory concentration (MIC):

The test was performed in duplicate exactly as described by **Senterfit (1983)**. The antimicrobials were tested in serial two fold dilutions at conc. ranging from 20 to 0.009 µg/ml.

End point reading:

The MIC is the lowest concentration of the antimicrobial that completely prevent a color change. This typically occurred after days. For comparison a final reading taken after 14 days incubation (**Whither *et al.*, 1983**). Results were expressed in µg/ml of the active material.

Results

Eighteen mycoplasma isolates and 3 aholeplasama species were isolated and identified from calves suffering from respiratory


signs in Dakahlia and Sharkia governorates as in Table (2). Six isolates from Dakahlia (16.7%) (4 *Mycoplasma bovirhinus* and 2 *Mycoplasma arginine*) and twelve isolates (26.7%) from Sharkia (2 *Mycoplasma bovirhinus*, 3 *Mycoplasma arginine* and 7 *Mycoplasma bovis*).

Table (2). Primary isolation, biochemical identification and PCR results of mycoplasma isolated from calves.

Governorate	samples Type	No.of Tested sample	Digitonin		Isolation %	Biochemical characterization						Identification		
						glucose		Arginin		Film&spo t		* <i>M.- bovirhinis</i>	** <i>M.Argi- nini</i>	*** <i>M.bovi s</i>
			+ve	-ve		+ve	-ve	+ve	-ve					
El Dakahlia	Nasal swab	36	6	2	16.7%	4	-	2		0		4	2	0
El Sharkia	Nasal swab	33	10	1	30.3	2	-	1		7		2	1	7
	Lung tissue	12	2	-	16.7	0	-	2		0		0	2	0
Total		81	18	3	22.2	6		5		7		6	5	7

* *Mycoplasma bovirhinis*** *Mycoplasma arginini** ** *Mycoplasma bovis*

Photo (1). Shows the electrophoretic pattern of common primer of Mycoplasma (16SrRNA) isolated from calves.



Lane: (1).100bp DNA ladder


Lane: (2). control positive

Lane: (5). control negative

Lane: (3, 4, and 6). *Mycoplasma species* isolated from calves.

This photo shows, the characteristic fragment of mycoplasma at 1000bp where four isolates characterized from diseased calves were subjected to examination by the common primer of ruminant (16SrRNA).

Photo (2). Shows the electrophoretic pattern of *Mycoplasma bovirhinis* by 16SrRNA specific gene.




Lane (1). 100bp DNA ladder

Lane (2). positive control

Lane (3-8). Field isolates from calves

This photo shows, the characteristic fragment of *Mycoplasma bovirhinis* at 316 bp where six isolates characterized from diseased calves were subjected to examination by the 16SrRNA specific primer.

Photo (3). Shows the electrophoretic pattern of *Mycoplasma bovis* by VspA gene.



Lane (1). 100bp DNA ladder

Lane (2). Negative control

Lane (3). positive control for *Mycoplasma bovis*

Lane (4-10). Field isolates from calves

This photo shows, the characteristic fragment of *Mycoplasma bovis* at 420 bp where seven isolates characterized from diseased calves were subjected to examination by the VspA gene.

Table (3). In vitro activities of five antimicrobials against Mycoplasma isolated from calves.

Mycoplasma isolates	Minimal inhibitory concentration				
	Draxxin	Enrofloxacin	Florofenicol	Oxytetracyclin	Tylosin
M.bovirhinis (2 isolate)	0.0048	0.048	0.048	0.058	0.039
M.arginini (3 isolate)	0.007	0.05	0.05	0.05	0.039
M.bovis (7 isolate)	0.078	0.014	0.156	0.078	0.039
C.Max µg (mcg)/mL	6.9	1.88	2	54.58	4.2

C-max: Maximum observed plasma concentration

Application of different antimicrobials as shown in table (3) and comparison of MIC to the C -max revealed that most of antibiotics used gave MIC less than C-max of the same antibiotics and we divided the activity of the antibiotics in relation to C-max. Draxxin has the lowest MIC for both Mycoplasma bovirhinis and mycoplasma arginine (0.0048-0.007), while, enrofloxacin has the lowest MIC for mycoplasma bovis (**0.014 µg/ml**) than other antimicrobials used in this study.

Discussion

Several species of mycoplasma may be isolated from calves with pneumonia but only few of these species are considered pathogenic. Respiratory pathogenic mycoplasma spp. includes *M.dispar*, *M. bovis*, *M.bovirhinis*, *M. bovis genitalium*, *Ureaplasma diversum*, (Nicholas *et al.*, 2000). Gourlay and Howard (1979), reported isolation of Mycoplasma from lungs of 30% of calves that died with severe pneumonia and 60% of calves with subclinical pneumonia, these results agree with our results where we were able to isolate mycoplasma from pneumonic lungs by 16.6% and from nasopharyngeal swabs by 16.7% in Dakahlia and 30.3% in Sharkia Governorates.

In this study, *M. bovirhinis* were identified in 7.4% of the samples examined and *M. arginine* by 6.17% while *M. bovis* could be isolated and identified in 8.64 %.

Prevalence of *M.bovis* is often underestimated in both beef and dairy herds because of the difficulties in diagnosis and the variety of clinical

signs associated with this infection and disease caused by this pathogen, Nicholas and Ayling (2003). Bacterial isolation which was considered the gold standard test for mycoplasma infections, is difficult and time consuming because of the fastidious nature of mycoplasmas, which require 1) specialized media and incubation conditions; 2) extended culture time as a result of the slow growth of the organism (up to 14 days for completion); and 3) additional testing for speciation. Khodakaram and Lopez (2004). Other respiratory pathogens are often isolated more easily and quickly, and attempts at detection and identification of *M. bovis* may not be pursued, (Haines *et al.*, 2001 and Freundt, *et al.*, 1973).

Transmission of *M.bovis* in respiratory secretions is considered important in the epidemiology of infection *M.bovis* may be transmitted in respiratory secretions via aerosols, nose to nose contact, or indirectly via feed, water, housing, or fomites. The importance of aerosols in calf to calf transmission of *M.bovis* is unknown, but *M.bovis* has been isolated from air in barns containing diseased calves (Jasper *et al.*, 1974), and calves can be experimentally infected by inhalation of *M.bovis*, (Nicholas *et al.*, 2002). This can explain the results of isolation of *M. bovis* from two farms in Sharkia Governorate.

A test based on PCR targeting 16SrRNA gene with mycoplasma specific primers and separation of the product according to the primer sequence using denaturing gradient gel electrophoresis (DGGE) has recently been applied for the detection of mycoplasma in samples (Laura *et al.*, 2003 and Blackburn *et al.*,

2010).

In our study we used three PCR assays, a common 16SrRNA gene can detect ruminant mycoplasma from calves as in photo 1, while, 16SrRNA specific gene of *M. bovirhinis* (Kobayashi *et al.*, 1998) gave specific band at 316 bp, this agree with our results as in photo 2. Using VspA gene for *M. bovis* we could identify seven strains as in photo 3, this agree with (Alberto *et al.*, 2006), who could isolate and identify *M. bovis* from cattle suffering from kerato-conjunctivitis.

Mycoplasma is very difficult to treat because many commonly used antibiotics do not work well. Penicillin kills bacteria by destroying the cell wall. Since *Mycoplasma* does not have a normal cell wall, these antibiotics are ineffective in treating it. Oxytetracycline has produced mixed results in treating *Mycoplasma*, in one study 50 percent of *M. bovis* isolates were resistant to oxytetracycline. Tulathromycin is the only drug approved for *Mycoplasma*, and in one study, was the drug most likely to be effective (Godinho *et al.*, 2005). In our study Tulathromycin was very effective in vitro on *M. bovirhinis* and *M. arginine* while oxytetracycline has the highest MIC on these strains. Enrofloxacin has the lowest MIC for *M. bovis* (0.014 µg/ml) than other antimicrobials used in this study, this agree with the results of Hannan *et al.* (1997) who found that enrofloxacin has the lowest MIC on *M. bovis* isolates.

References

- Alberto, A.; Addis, M.F.; Cheessa, B.; Cubaddu, T.; Profiti, M.; Rosati, S.; Ruiu, A. and Pittau, M. (2006). Molecular and antigenic characterization of a mycoplasma bovis strain causing an outbreak of infectious kerato-conjunctivitis. J. vet. diagn. Invest. 18:41-51.
- Blackburn, P; McAuliffe, L.; Nicholas, R.A., and Ball, H.J., (2010). Comparison of methods for detecting mycoplasmas in calf pneumonia cases. Veterinary Record; 166:561-562 doi:10.1136/vr.b4833.
- Duchemin, D. (2004). Pathology of veal calf-relation with the age. In: Proceedings of the 23rd World Buiatrics Congress, Quebec, Canada, p. 97.
- Erno, H. and Stipkovits, L., (1973). Bovine mycoplasma cultural and biochemical studies. Acta Vet. Scand. 14:454-463.
- Fan, H. H., Kleven, S. H., and Jackwood, M. W. (1995). Application of polymerase chain reaction with arbitrary primers to strain identification of *Mycoplasma gallisepticum*. Avian Dis., 39(4). 729-735.
- Franco D, Fecteau G, Desrochers A. and Fortin, M.M., (2004). Otitis media in dairy calves: A retrospective study of 15 cases (1987 to 2002) can vet J: 45:661-666.
- Freundt, E.A.; Anderws, B.E; Erno, H; Keenez, M. and Black, F.T. (1973). The sensitivity of mycoplasmales to sodium polyanthol sulphonate and digitonin. Zbl Bact. Hgy. In Abt. Orig. A, 225:104-112.
- Ganaba, R., Bigras-Poulin M., Belanger, D. and Y. Couture, (1995). Description of cow-calf productivity in Northwestern Quebec and path models for calf mortality and growth. Prev. Vet. Med., 24:31-42.
- Godinho, K.S., PSarasola, J. Sherington, T.G. Rowan and J. Sunderland, (2005). Evaluation of tulathromycin (Draxxin) for the treatment and prevention of bovine respiratory disease under natural conditions. Res. Vet. Med., 156:437-444.
- Gourlay, R.N. and Howard, C.J. (1979). Bovine *Mycoplasma* spp. 49-102. In: The Mycoplasmas, Vol II, Human and Animal mycoplasmas (Tully, J.G. and Whitcomb, R.F. eds). Academic press, New York.
- Haines, D.M., Martin K.M., Clark E.G., Jim G.K., and Janzen E., (2001). The immunohistochemical detection of mycoplasma bovis and bovine viral diarrhoea virus in tissue of feed lot cattle with chronic unresponsive respiratory disease and/or arthritis. Can vet j. 42 857-860.
- Hannan, P.C.T; Windsor, G.D; Jong, A.D.E; Schmeer, N and M. Stegemann, (1997). Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrobial agents and chemotherapy.

- apy,41:2037-2040.
- Jasper D E, Alaubaid JM, and Fabrican J., (1974).** Epidemiologic observations on mycoplasma mastitis. *Cornell vet.* 64:407-415.
- Khodakaram-Tafti A. and Lopez A. (2004)** Immunohistopathological findings in the lungs of calves naturally infected with *Mycoplasma bovis*. *J Vet Med. A Physiol Pathol Clin Med.*51:10–14.
- Kobayashi, H., Kazuhiko,H., Apasara, W., Patchara,P., Nobuyoshi ITO., Tetsuo Morozumi and Yamamoto, K.,(1998).** *InVitro* Amplification of the 16SrRNA Genes from *Mycoplasma bovirhinis*, *Mycoplasma alkalescens* and *Mycoplasma bovigenitalium* by PCR. *J.Vet Med.Sci.*,60 (12).1299-1313.
- Lamm CG, Munson L. and Thrmond MC. (2004).** Mycoplasma otitis in Californicalves. *J Vet Diagn Invest* 2004;16:397-402.
- Laura McAuliffe, Richard J.Ellis, Roger D.Ayling, and Robin A. J. Nicholas (2003).** Differentiation of Mycoplasma species by 16S Ribosomal DNA PCR and Denaturing Gradient Gel Electrophoresis Fingerprinting, *Journal of clinical Microbiology*, October 2003, p.4844-4847, Vol.41, No.10.
- Nicholas RA and Ayling RD. (2003).** *Mycoplasma bovis* disease, diagnosis and control. *Res Vet. Sci.*:74:105-112.
- Nicholas RA, Ayling RD. and Stipkovits LP. (2002).** An experimental vaccine for calf pneumonia caused by *Mycoplasma bovis*: Clinical, cultural, serological and pathological findings, *Vaccine* :20:3569-3575.
- Nicholas RA, Barker, and Rayling, R.,(2000).** Mycoplasma infections in growing cattle. *Cattle practice* 8, 2: 115-118.
- Sabry, H.Z and Ahmed, A.A. (1975).** "Evaluation of culture procedure for primary isolation of mycoplasma from female genitalia of farm animals" *J.Egypt, Vet. Med. Ass.*, 35:18-34.
- Sayed, S.M. and A.M.A. Zaitoun, (2009).** Aerobic bacterial pathogens of pneumonic feedlot buffalo-calves, Assiut governorate, Egypt, *Ass. Uni. Bull. Environ. Res.*, 12:55-62.
- Senterfit, L.B. (1983).** Antibiotic sensitivity testing of mycoplasmas. In *Methods in mycoplasmaology*, Vol. II. Academic press, pp.397-401.
- Sharter FM, Clark EG, Janzeen E, West K. and Wobeser, G., (2002).** Coinfection with bovine viral diarrhea virus and mycoplasma bovis in feedlot cattle with chronic pneumonia *Can vet j*;43 863-868.
- Taylor-Robinson, D. (1983).** Metabolism inhibition tests in: Tully, J.G. and Razin, S. (Eds) *Methods in mycoplasmaology*, Vol. I. Academic press, PP. 411-417.
- Thomas, A. and Ball H.D. (2002).** Isolation of mycoplasma species from the lower respiratory tract of healthy cattle with respiratory disease in Belgium. *Vet Rec.*151:472-476.
- Virtala, A.M., Mechor, G.D., Grohn, Y.T., Erb, H.N. and Dubovi, E.J. (1996).** Epidemiologic and pathologic characteristics of respiratory tract disease in dairy heifers during the first three months of life. *Journal of American Veterinary Medical Association* 208, 2035–2042.
- Whithear, K.G., D.D. Bowtell. E. Ghiocas and Hughes, K.L. (1983).** Evaluation and use of a micro-broth dilution procedure for testing sensitivity of fermentative avian mycoplasmas to antibiotics. *Avian Dis.*, 27:937-949.
- Wiggins, M.C., Woolums, A.R. and Sanchez, S. (2007).** Prevalence of *Mycoplasma bovis* in back grounding and stocker cattle operations *J AM Vet Med Assoc.*:230:1514-1518.

دراسات عن الاصابات التنفسية بالميكوبلازما فى العجول فى محافظتى الدقهلية و الشرقية. عيد السعيد ، منسى أحمد دردير ، محمد فوزى طه ، عبد الواحد حسن ، منى شاكر

الملخص العربى

تم عمل هذه الدراسة على العجول التى تعاني من أعراض تنفسية و ارتفاع فى درجة الحرارة وفقدان فى الشهية وكانت الاعمار تتراوح بين شهرين الى سنتين ذلك قبل بدأ اعطاء العلاج حيث تم تجميع عدد 81 عينة (69 مسحة من الانف و البلعوم و 12 عينة من أنسجة من الرئتين) من محافظات الدقهلية و الشرقية-مصر و تم عزل الميكوبلازما من محافظة الدقهلية بنسبة 16.7% و من محافظة الشرقية بنسبة 26.7% حيث تم تصنيف 6 معزولات من الميكوبلازما بوفيرينس، 5 معزولات من الميكوبلازما أرجينيني و 7 معزولات من الميكوبلازما بوفيس و كانت معزولات الميكوبلازما بوفيس من مزرعتين فقط من محافظة الشرقية. تم تصنيف المعزولات بالاختبارات البيوكيميائية و اختبار أنزيم البلمرة المتسلسل (PCR) باستخدام جين ال 16SrRNA و من خلاله تم تأكيد العزل الذى يعطى حزمة مميزة عند 1000bp و تم تأكيد تصنيف معزولات الميكوبلازما بوفيس باستخدام جين VspA و الذى يعطى حزمة مميزة عند 400bp . باجراء اختبار الحساسية لبعض المعزولات الممثلة بطريقة أقل تركيز مثبت MIC و مقارنته بأعلى تركيز للمضاد الحيوى فى جسم الحيوان C-MAX وجد أن عقار الدراكسين (التولاثرومايسين) أكثر تأثيرا على ميكوبلازما بوفيرينس و ميكوبلازما أرجينيني بأقل تركيز مثبت ≥ 0.0048 و أقل من C-MAX لنفس المضاد , بينما كانت معزولات الميكوبلازما بوفيس أكثر تأثرا بعقار الانروفلوكساسين بأقل تركيز مثبت ≥ 0.014 و أقل من C-MAX لنفس المضاد.